Skip to main content

Pylarify Dosage

Generic name: PIFLUFOLASTAT F-18 80mCi in 1mL
Dosage form: injection
Drug class: Diagnostic radiopharmaceuticals

Medically reviewed by Last updated on Jan 14, 2022.

Radiation Safety – Drug Handling

PYLARIFY is a radioactive drug. Only authorized persons qualified by training and experience should receive, use, and administer PYLARIFY. Handle PYLARIFY with appropriate safety measures to minimize radiation exposure during administration [see Warnings and Precautions (5.3)]. Use waterproof gloves and effective radiation shielding, including syringe shields, when preparing and handling PYLARIFY.

Recommended Dosage and Administration Instructions

Recommended Dose

The recommended amount of radioactivity to be administered for PET imaging is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi) administered as a single bolus intravenous injection.

Preparation and Administration

  • Use aseptic technique and radiation shielding when preparing and administering PYLARIFY.
  • Visually inspect the radiopharmaceutical solution. Do not use if it contains particulate matter or if it is discolored (PYLARIFY is a clear, colorless solution).
  • Calculate the necessary volume to administer based on calibration time and required dose. PYLARIFY may be diluted with 0.9% Sodium Chloride Injection, USP.
  • Assay the dose in a suitable dose calibrator prior to administration.

Post Administration Instructions

  • Follow the PYLARIFY injection with an intravenous flush of 0.9% Sodium Chloride Injection USP.
  • Dispose of any unused PYLARIFY in compliance with applicable regulations.

Patient Preparation

Instruct patients to drink water to ensure adequate hydration prior to administration of PYLARIFY and to continue drinking and voiding frequently for the first few hours following administration to reduce radiation exposure [see Warnings and Precautions (5.3)].

Image Acquisition

The recommended start time for image acquisition is 60 minutes after PYLARIFY injection. Starting image acquisition more than 90 minutes after injection may adversely impact imaging performance. Patients should void immediately prior to image acquisition. Position the patient supine with arms above the head. Image acquisition should start from mid-thigh and proceed to the skull vertex. Scan duration is 12 minutes to 40 minutes depending on the number of bed positions (typically 6 to 8) and acquisition time per bed position (typically 2 minutes to 5 minutes).

Image Display and Interpretation

PYLARIFY binds to prostate-specific membrane antigen (PSMA). Based on the intensity of the signals, PET images obtained using PYLARIFY indicate the presence of PSMA in tissues. Lesions should be considered suspicious if uptake is greater than physiologic uptake in that tissue or greater than adjacent background if no physiologic uptake is expected. Tumors that do not express PSMA will not be visualized. Increased uptake in tumors is not specific for prostate cancer [see Warnings and Precautions (5.1)].

Radiation Dosimetry

Radiation absorbed dose estimates are shown in Table 1 for organs and tissues of adult male patients from intravenous administration of PYLARIFY. The radiation effective dose resulting from administration of 370 MBq (10 mCi) of PYLARIFY to an adult weighing 70 kg is estimated to be 4.3 mSv. The radiation doses for this administered dose to the critical organs, which are the kidneys, liver, and spleen, are 45.5 mGy, 13.7 mGy, and 10 mGy respectively. When PET/CT is performed, exposure to radiation will increase by an amount dependent on the settings used in the CT acquisition.

Table 1. Estimated Radiation Absorbed Doses in Organs/Tissues in Adults who Received PYLARIFY
Organ/Tissue Mean Absorbed dose per Unit Administered Activity
Mean Standard Deviation
Adrenal glands 0.0131 0.0013
Brain 0.0021 0.0003
Breasts 0.0058 0.0007
Gallbladder wall 0.0141 0.0012
Lower large intestine wall 0.0073 0.001
Small intestine 0.0089 0.0009
Stomach wall 0.0092 0.0008
Upper large intestine wall 0.0091 0.0009
Heart wall 0.0171 0.0022
Kidneys 0.123 0.0434
Liver 0.037 0.0058
Lungs 0.0102 0.0016
Muscle 0.0069 0.0008
Pancreas 0.0124 0.0011
Red bone marrow 0.0071 0.0007
Osteogenic cells 0.0099 0.0012
Skin 0.0052 0.0006
Spleen 0.0271 0.0115
Testes 0.0059 0.0008
Thymus gland 0.007 0.0008
Thyroid 0.0062 0.0009
Urinary bladder wall 0.0072 0.001
Effective dose 0.0116 (mSv/MBq) 0.0022 (mSv/MBq)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.